Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for April 2012
April 2, 2012
- Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer
- BioScale Presents Data from a Novel Signal Transduction Pathway Analysis Using AMMP Assays at the 2012 American Association of Cancer Research (AACR) Meeting
- Novartis QVA149 Phase III COPD studies meet primary endpoints
- Transgenomic, Inc. Announces Presentation of Results from 448-Gene NuclearMitome Test in 78 Patients at the 2012 Annual Meeting of the American College of Medical Genetics
- ARIAD Presents New Preclinical Data on Ponatinib and AP26113
- Efficacy and Safety Data for ZOSTAVAX (Zoster Vaccine Live), Merck's Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases
- Promising Data Presented at AACR Further Support New Lung Cancer Treatment Combination as Well as Ongoing Studies of Peregrine's Bavituximab
- Investigational Targeted Drug Induces Responses in Aggressive Lymphomas
- Biocept to Present at the 103rd AACR Annual Meeting on New Analytic Methods for Circulating Tumor Cell Analysis, Including SelectorTM, Ultra-Sensitive Mutation Detection Technology
- Lilly Targets Faulty c-MET Receptor in Cancer Research Studies Presented Today at AACR Meeting
- CTNeT Selects Medidata Solutions as Strategic IT Partner
- QVA149 Phase III COPD Studies Met Primary Endpoints
- Tetraphase Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates
- Measles-Containing Vaccines not Associated with Increased Risk of Febrile Seizures in Children Ages 4-6
- Cabozantinib to be Featured in Nine Presentations at 2012 ASCO Annual Meeting
- Sangamo BioSciences Announces Publication in Nature Medicine Demonstrating Use of ZFN Technology to Engineer Safer and More Effective Cancer Treatments
- Keryx Biopharmaceuticals Announces Top-Line Data from the Perifosine (KRX-0401) X-PECT Phase 3 Clinical Trial
- Oncoprex Shows Synergistic Tumor Suppression in Combination with AKT Inhibitor MK2206
- Infinity Reports New Preclinical Data for Saridegib at AACR Supporting Development in Residual Disease Settings
- Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV
April 3, 2012
- GSK Receives Further Data from Phase lll Studies of Albiglutide in Type 2 Diabetes
- Aeterna Zentaris Presents Preclinical Data for Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, at AACR Meeting
- Acceleron's ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma
- Navidea Biopharmaceuticals Presents Favorable Comparison of Lymphoseek to Sulfur Colloid at Sentinel Node Oncology Foundation and Sentinel Lymph Node Working Group
- Phase III Trial of Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival
- Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACR
- TetraLogic Pharmaceuticals Announces Presentation of Preclinical Data on Birinapant (TL32711) in Pancreatic Cancer and Lymphoma at the 103rd AACR Annual Meeting 2012
- Codexis and Merck Develop Prototype Enzyme-Based Method for Production of Boceprevir
- Esperance Pharmaceuticals Presents Poster at AACR Annual Meeting Demonstrating Synergy of Lead Candidate EP-100 with Paclitaxel in In Vitro Studies
- Unigene's Proprietary Oral Peptide Delivery Platform is Further Validated with Cara Therapeutics' Successful Completion of its Phase 1 Study Using Unigene's Oral Formulation of Novel Kappa Opioid Receptor Agonist, CR845
April 4, 2012
- Phase III Trial of Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival
- Aeterna Zentaris Presents Preclinical Data for Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, at AACR Meeting
- Aeterna Zentaris Presents Preclinical Data for Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, at AACR Meeting
- Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 MDS and AML Data Presentation at AACR
- Phase 2 Clinical Trial Results: VEN100 Reduces Antibiotic-Associated Diarrhea by 50% in High-Risk Patients
- Synta Announces Results on Ganetespib Across a Range of Malignancies at the American Association for Cancer Research (AACR) Annual Meeting
- Encouraging Selumetinib Results Announced for Phase 2 Trial in Ovarian Cancer
- Bristol-Myers Squibb to Present New Data Demonstrating Company's Commitment to Research and Development in Liver Disease at The International Liver CongressTM / European Association for the Study of the Liver (EASL) Annual Meeting
- Abbott to Present Positive Phase 2 Results from Multiple Interferon-Free Studies of Combination Regimens for the Treatment of Hepatitis C
- Medivir Announces Acceptance of Four TMC435 Abstracts for Presentation at the EASL Meeting
- BIND Biosciences Presents Clinical Data on BIND-014 Promising Anti-tumor Effects in Patients with Advanced or Metastatic Cancers
- EpiCept's Licensed Compound EP1013 Identified as a New Drug Candidate for Treatment of Late-Stage Viral Hepatitis
- Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
- Trillium provides update on anti-CD47 cancer program
- Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin at the AACR Annual Meeting
- BIND Biosciences Publishes Data on BIND-014, the First Targeted and Programmable Nanomedicine to Show Clinical Anti-Tumor Effects
- Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
- Perceptive Informatics Global Survey Results Show Significant Adoption of Web-based RTSM Systems by Clinical Site
April 5, 2012
- Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials
- Positive Top-Line Results from Phase 3 Long-term, Open-label Safety and Efficacy Trial of Lubiprostone in Opioid-Induced Bowel Dysfunction Patients
- Antipsychotic Drug May Be Helpful Treatment for Anorexia Nervosa
- Zalicus Discovers Novel Multi-Target Mechanism for the Treatment of Multiple Myeloma
- Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, Oral Anemia Treatment, AKB-6548
- Molecular Partners Comments on Allergan's Progress in Phase IIa Retinal Disease Trial Using Anti-VEGF DARPin®
- New Stem Cell Line Provides Safe, Prolific Source for Disease Modeling and Transplant Studies
- TONIX Pharmaceuticals Completes Pharmacokinetic Study on New Formulation of TNX-102 for Fibromyalgia
April 6, 2012
April 9, 2012
- Genes Identified for Common Childhood Obesity
- Data Show Gilead?s Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study
- Stealth Peptides Inc. Reports Results from Phase I Clinical Drug Interaction Studies with Bendavia
- Investigators at Children's Hospital Los Angeles Discover Possible Treatment Option for Drug-Resistant Acute Lymphoblastic Leukemia
- SCOLR Pharma's Partner Announces Positive Preliminary Results in Ondansetron Study
- Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound
- Novel Compound Demonstrates Anti-Leukemic Effect in Zebrafish, Shows Promise for Human Treatment
- OphthaliX Successfully Completed Preclinical Studies Showing the Efficacy of CF101 for the Treatment of Anterior Uveitis
April 10, 2012
- Phase 2 Data on Provectus's PV-10 to Be Presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012
- Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of TC-6987 in Asthma
- PHT Corporation Named to Boston Business Journal's 2012 Pacesetters List of Fastest Growing Private Companies in Massachusetts
April 11, 2012
- Novel T Cell Antigen Discovery Platform Providing New Momentum on Malaria Vaccine
- Simulations Plus Announces Further Success in Malaria Drug Design Project
- Cannabis Science Receives New Photos and Positive Feedback from Patient Three and an Oncologist about his Severe Squamous Cell Carcinoma
- GE Healthcare Announces Preliminary Phase 3 Results for Flutemetamol
April 12, 2012
- AVEO Announces Publication of Positive Tivozanib Phase 2 Clinical Trial Results in Journal of Clinical Oncology
- Perceptive Informatics Enables Greater Trial Supply Efficiency With New Site Inventory Management Module
- MD Becker Partners Releases White Paper: ?2012: A Pivotal Year for Alzheimer's Disease Drug Development?
- Montefiore Study Reveals High Rate of Anal Cancer in HIV-positive Women
- Fine-Scale Analysis of the Human Brain Yields Insight Into its Distinctive Composition
- Does Estrogen-Only HRT Decrease Breast Cancer Risk? Nationally Recognized Endocrinologist Dr. Marina Johnson Weighs In
April 13, 2012
April 16, 2012
- Medtronic Endurant AAA Stent Graft Shows Durable Performance at Two Years in U.S. Study
- Medidata Solutions Helps RTI International Address Evolving Research Technology Needs
- Cutting Edge Information Launches New Customized Benchmarking Service for Medical Science Liaisons
- Cimzia (certolizumab pegol) shows positive top-line phase 3 results in axial spondyloarthritis and ankylosing spondylitis
- Galectin Therapeutics to Present Promising New Therapeutic Approach for Fatty Liver Disease at Digestive Disease Week 2012
- Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations
- Data from FzioMed's Oxiplex U.S. Pivotal Clinical Study Published in Spine
- Certara Releases Major Advance to Phoenix Software Platform
April 17, 2012
- PROLOR Biotech Announces Positive Results of Its Obesity/Diabetes Drug Candidate in Preclinical Weight Loss Study
- Melior Discovery Announces Two Publications Describing New Therapeutic Opportunity In Diabetes
- Adding Drug to Standard Chemotherapy Provides no Survival Benefit for Older Lung Cancer Patients
April 18, 2012
- Inform Genomics Announces Results of Study Predicting Risk of Oral Mucositis in Patients Undergoing High Dose Chemotherapy
- Gilead Sciences to Present New Hepatitis B and C Data at European Conference on Liver Disease This Week
- RedHill Biopharma Announces a Successful Pivotal Bioequivalence Trial with RHB-102 for the Prevention of Nausea and Vomiting in Cancer Patients
- Nuvilex Announces Invitation to Showcase Innovative Therapy for Cancer Treatment at Oncology Meeting in Kyoto, Japan
- Scripps Research Institute Scientists Develop Antidote for Cocaine Overdose
- Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference
- ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients
- Abbott's Investigational Treatment for Advanced Parkinson's Disease Demonstrates Positive Results in Phase 3 Clinical Trial
- Celek Pharmaceuticals to Present Recent Progress on its Anticancer Drug Candidate, CEL-031, at National Cancer Institute Investor Forum
- INCIVO (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naive and Previously Treated Patients With Genotype-1 Chronic HCV
- New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa(R) (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY(R) Trial
- Cubist Announces Positive Results from ENTEREG Phase 4 Study in Patients Undergoing Radical Cystectomy
- Scientists Report that Process of Converting Non-Beating Heart Cells into Functional, Beating Heart Cells is Enhanced Using Thymosin Beta 4 in Conjunction with Gene Therapy
- UCB Sponsors Data Presentations on Epilepsy and Vimpat (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology
- Synta Announces Results Demonstrating Potent Ganetespib Activity across Broad Range of Crizotinib-Resistant ALK+ NSCLC models at the European Lung Cancer Conference
- Teva Announces New Data on Central Nervous System Products to Be Presented at 2012 American Academy of Neurology Annual Meeting
- Groundbreaking Research Has Promise for Treatment and Prevention of Cancers Caused by Viruses
- NIH research team housed at DMC/WSU publishes major study demonstrating that there is a window of opportunity to prevent cerebral palsy
- New Research Finds Health Care Remains a Key Concern for Americans
- Prolor Biotech Announces Positive Results of Its Obesity/Diabetes Drug Candidate in Preclinical Weight Loss Study
April 19, 2012
- Merck Reports Phase III Study Results Evaluating Anemia Management Strategies Used With Victrelis (boceprevir) Combination Therapy
- Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
- Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients
- Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C
- All-Oral Combination of Investigational Hepatitis C (HCV) Compounds Daclatasvir and GS-7977 Achieved Sustained Virologic Response (SVR4) in 100% of Genotype 1 and 91% of Genotype 2 and 3 Treatment-Naïve Patients in Phase II Study
- Roche reports high rates of sustained viral clearance with investigational hepatitis C treatment danoprevir
- Study Evaluating Anemia Management Strategies Used with VICTRELIS (boceprevir) Presented at International Liver Conference
- Neurology Publishes Results From Pivotal Study Of Eisai's Perampanel
- CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
- Landmark IOM Report Shows 1 in 26 will have Epilepsy in Lifetime
- Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C
- Investigational Compound Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Flu-Like and Musculoskeletal Symptoms in Phase IIb Study in Treatment-Naïve Genotype 2 or 3 Hepatitis C Patients
- Study: Use of Drug Following First Sign of Possible MS Reduces Likelihood of Progression to MS
April 20, 2012
April 23, 2012
- Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C
- Once-daily oral anticoagulant receives positive Common Drug Review recommendation for stroke prevention in atrial fibrillation
- Tekmira?s LNP Technology Enables Alnylam?s Positive ALN-PCS Clinical Data
- PolyMedix Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic
- Two phase 3 studies on ultra-long-acting insulin degludec published today in The Lancet
- MicuRx Pharmaceuticals Completes Phase 1 Trial For MRX-I, A Next-Generation Antibiotic
- PerkinElmer Launches Ensemble for Biology Informatics Platform
- Aptiv Solutions Announces the Launch of ADDPLAN 6.0 PE Adaptive Design & Simulation Software for Population Enrichment Trials
April 24, 2012
- MicroDose Therapeutx Announces Conclusion of MDT-637 Phase I Single and Multiple Ascending Dose Studies in Healthy Volunteers for Treatment of Respiratory Syncytial Virus (RSV)
- Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C
- QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149
- Adocia reports positive phase II clinical results for the treatment of diabetic foot ulcer
- Positive Results from Phase 3 CONFIRM Clinical Trial Show Efficacy and Safety of Oral BG-12 in Multiple Sclerosis
- Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
- Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif® in Phase III Trial
April 25, 2012
- Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy
- Acorda Therapeutics Presents AMPYRA Long-Term Safety and Efficacy Data at 64th American Academy of Neurology Annual Meeting
- Botox Injections Associated With Only Modest Benefit for Chronic Daily Headaches and Chronic Migraine Headaches
- Soligenix Announces Further Progress with ThermoVax for Long-Term Vaccine ThermoStability
- Phase 3 Results for GE Healthcare Imaging Agent Flutemetamol Presented at American Academy of Neurology Meeting
- Study Points to Potential Treatment for Stroke
- New Nano Technique Determines Agressiveness of Prostate Cancer
- Study Findings Confirming Reliable Beta-Amyloid Imaging in the Living Brain Presented at AAN Annual meeting in New Orleans
- First Assessment of Individual RLS Domains in New Post-Hoc Analyses of Neupro Studies
- Online Business Applications Releases Web-Based IRMS-CE
- KYTHERA Biopharmaceuticals Announces Positive Results from Two Pivotal European Phase III Trials of ATX-101 for Reduction of Submental Fat
April 26, 2012
- Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients with Major Depressive Disorder
- Shire Reports Positive Phase 2 Study Met Primary End Point for Investigative Use of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in Adults with Binge Eating Disorder
- Preliminary Data Suggest Spasticity May Be Reduced in Relapsing-Remitting Multiple Sclerosis Patients Who Transitioned to Teva's COPAXONE®
- Interim results of VITOBA (VImpaT added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
- New TYSABRI Data Presented at 64th Annual AAN Meeting Highlight Biogen Idec & Elan Commitment to Improving Outcomes in Multiple Sclerosis
- miRagen Therapeutics Announces the Publication of Compelling Data Suggesting the MIRG-9103 Program May Have Utility in Treating Multiple Disorders Associated with Metabolic Syndrome
- New Post-Hoc Analyses Examined Neupro Effects on Pain, Depressed Mood, Apathy and Fatigue in Patients with Parkinson's Disease
- Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
April 27, 2012
- Generex Announces Publication of Paper on Buccal Spray Insulin
- Nordson Micromedics Releases Clinical Study Data on Assisted Injection vs. Manual Injection of Dermal Fillers
- Baxter Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Neuropathy at AAN Annual Meeting
- Agent Reduces Autism-Like Behaviors in Mice
- Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
- Results From Chelsea Therapeutics' Pivotal Northera (Droxidopa) Study to be Presented at the American Academy of Neurology's Annual Meeting
- Octagon Discusses Regulatory Information Management Best Practices in Europe
April 30, 2012
- 2 Drugs Better Than 1 to Treat Youth With Type 2 Diabetes
- Ampio Pharmaceuticals announces extended analysis of Ampion In the Knee (AIK) Study shows pain relief of osteoarthritis, 84 days after a single injection into the knee, is statistically significant
- Actelion's Macitentan Meets Primary Endpoint in Pivotal Phase III SERAPHIN Outcome Study in Patients With Pulmonary Arterial Hypertension
- New research expands understanding of psychoactive medication use among children in foster care
- TKL Research Selects Medidata Solutions' Clinical Trial Management System to Drive Future Growth
- Syndax Pharmaceuticals Announces Publication of Entinostat Phase 2 Clinical Trial Data in Journal of Clinical Oncology
- Amylin Pharmaceuticals to Present at Deutsche Bank 37th Annual Health Care Conference
- About one baby born each hour addicted to opiate drugs in U.S., U-M study shows
